<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this randomised controlled trial was to compare efficacy and safety of two doses of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (enoxaparin) in pregnant women with a history of <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortion</z:e> secondary to <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 60 women with a minimum of three consecutive abortions before 10 weeks' gestation and positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and/or anticardiolipin antibodies on at least two occasions at least 12 weeks apart were randomised into two groups based on computer generated randomisation list concealed in opaque envelopes </plain></SENT>
<SENT sid="2" pm="."><plain>Pregnant women were treated with enoxaparin 40 mg plus low dose aspirin (LDA) (n = 30) or enoxaparin 20 mg plus LDA (n = 30) </plain></SENT>
<SENT sid="3" pm="."><plain>The live birth rate was 76.67% in enoxaparin 40 mg group and 70% in enoxaparin 20 mg group (p value = 0.559) </plain></SENT>
<SENT sid="4" pm="."><plain>There were no significant differences between both groups with respect to neonatal outcome, obstetric and maternal complications during pregnancy or puerperium </plain></SENT>
<SENT sid="5" pm="."><plain>No cases of severe <z:mp ids='MP_0001914'>bleeding</z:mp>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or <z:hpo ids='HP_0002756'>spontaneous fractures</z:hpo> were reported in both groups </plain></SENT>
</text></document>